ACCESSWIRE

The Klein Law Firm

Share
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PRVB, WPG and REKR

NEW YORK, NY / ACCESSWIRE / July 15, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Provention Bio, Inc. (NASDAQ:PRVB)
Class Period: November 2, 2020 - April 8, 2021
Lead Plaintiff Deadline: July 20, 2021

Throughout the class period, Provention Bio, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in PRVB: https://www.kleinstocklaw.com/pslra-1/provention-bio-inc-loss-submission-form?id=17668&from=1

Washington Prime Group, Inc. (NYSE:WPG)
Class Period: November 5, 2020 - March 4, 2021
Lead Plaintiff Deadline: July 23, 2021

The WPG lawsuit alleges that throughout the class period, Washington Prime Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) WPG's financial condition was deteriorating substantially; (2) as a result, there was substantial uncertainty about the Company's ability to meet its capital structure obligations as they became due; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in WPG: https://www.kleinstocklaw.com/pslra-1/washington-prime-group-inc-loss-submission-form?id=17668&from=1

Rekor Systems, Inc. f/k/a Novume Solutions, Inc. (NASDAQ:REKR)
Class Period: April 12, 2019 - May 25, 2021
Lead Plaintiff Deadline: August 30, 2021

The complaint alleges that throughout the class period Rekor Systems, Inc. f/k/a Novume Solutions, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Rekor's automatic license plate recognition ("ALPR") technology and uninsured vehicle enforcement diversion ("UVED")-related business is outclassed by global competitors with an established, dominant market share; (ii) it was unlikely that states would pass legislation authorizing deals similar to Rekor's Oklahoma UVED partnership because of, inter alia, state and local privacy laws and related public concerns; (iii) Rekor's UVED partnership was not as profitable as Defendants had led investors to believe because of known impediments to enrollment rates and costs associated with the partnership; (iv) accordingly, Rekor had overstated its potential revenues, profitability, and overall ALPR- and UVED-related business prospects; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in REKR: https://www.kleinstocklaw.com/pslra-1/rekor-systems-inc-f-k-a-novume-solutions-inc-loss-submission-form?id=17668&from=1

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/655659/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-PRVB-WPG-and-REKR

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESSWIRE

DK

Subscribe to releases from ACCESSWIRE

Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESSWIRE

Opti Digital Breaks Down the Biggest AdTech Trends in 202518.10.2024 03:40:00 CEST | Press release

As the ad tech landscape evolves, 2025 promises to be a pivotal year for digital advertising, with key trends already emerging. BARCELONA, SPAIN / ACCESSWIRE / October 18, 2024 / Magali Quentel-Reme, CEO of Opti Digital; Mohsin Pervez, Senior Director of Platform Solutions and Operations, EMEA at PubMatic; and Langdon Miller, Director of Programmatic at Brainly, share their insights on the future of the AdTech landscape and the key trends set to shape programmatic in 2025. Addressability Solution With over 50% of third-party cookies already phased out and Google's pivotal July 2024announcement granting users control over cookie settings, the need for effective alternatives is more critical than ever. Langdon Miller, Director of Programmatic at Brainly, explains that "the integration of probabilistic and deterministic IDs, first-party data, contextual segmentation, and bid decoration has led to sustained performance and increased yield." This is echoed on the buy side, with a growing re

Participation in the Multilateral System Remains High as Performance Drops, New Index Finds17.10.2024 13:00:00 CEST | Press release

The Multilateralism Index 2024 reveals a contradiction: while participation in the multilateral system has largely held steady or even increased, its effectiveness in addressing global challenges has declined. WASHINGTON, DC / ACCESSWIRE / October 17, 2024 / Today marks the launch of the second edition of the Multilateralism Index from the International Peace Institute (IPI) and the Institute for Economics & Peace (IEP). The Index reveals that states remain engaged in the global multilateral system even as it increasingly struggles to address the crises it faces. Multilateralism Index 2024 Report An image of the front cover of the Multilateralism Index 2024 Report Key results The performance of the multilateral system declined across all five domains examined. Peace and security showed the steepest deterioration in performance, with the number of armed conflicts rising from 39 in 2013 to 55 in 2022. Climate action and human rights also saw significant declines in performance, despite i

Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells16.10.2024 09:00:00 CEST | Press release

ATH-063 significantly increased the number of circulating regulatory T cells (Tregs) across all doses and demonstrated enrichment in six well-described genes related to induced Treg anti-inflammatory activities No serious adverse effects or dose limiting toxicities were observed at any dose level, and ATH-063 demonstrated favorable pharmacokinetics (PK) The data provides clinical verification for Athos' Proprietary AI2 (Artificial Intelligence for Autoimmune drug development) computational software platform which generated ATH-063 LOS ANGELES, CA / ACCESSWIRE / October 16, 2024 / Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, today announced topline results for the company's Phase 1 clinical trial of ATH-063, an investigational oral small molecule G9A inhibitor and the company's lead asset in development for the treatment of inflammatory bowel dise

Probabl (The Official Operator of the Scikit-Learn Brand) Selects Kryterion to Provide Certification to Millions of Data Scientists in Machine Learning16.10.2024 08:40:00 CEST | Press release

HARROW, UK / ACCESSWIRE / October 16, 2024 / Kryterion, a leader in certification test development and delivery solutions, was selected by Probabl, the official operator of the scikit-learn brand, to deliver the first-ever official certification programme targeting millions of data scientists. The scikit-learn software library has registered over 1.5 billion downloads and is the gold standard for open-source machine learning in the Python ecosystem, underpinning over 1 million global projects. Kryterion's proven track record as a secure, scalable certification platform makes it the ideal partner for delivering this groundbreaking programme. Kryterion & Probabl Probabl and Kryterion will support the global data science community by offering the first globally recognised certification in scikit-learn. As the official operator of the scikit-learn brand, Probabl is spearheading the initiative to provide structured certification across three key tiers: associate, professional, and expert. T

Moolec Has Received USDA Approval for the First Genetically Modified Pea in History16.10.2024 06:00:00 CEST | Press release

LUXEMBOURG / ACCESSWIRE / October 16, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance from USDA-APHIS achieved by Moolec in an 18-month window, alongside its genetically engineered safflower and soybean for GLASO™ and Piggy Sooy™ products, respectively. Access the official USDA-APHIS publication here. "With USDA approval for our GE pea, Moolec has now secured regulatory clearance for all of our key crops in the US: safflower, soybean, and pea," said Gastón Paladini, CEO and Co-Founder of Moolec. "We are proud to be the only Molecular Farming company with three US regulatory approvals and a major commercial contract. This milestone

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye